Dana Andersen joined Denali Therapeutics in 2018 as the Chief Technical and Manufacturing Officer and is responsible for overseeing the development of manufacturing processes, production, quality control & assurance and clinical supply to support the Denali portfolio.
Previously, he worked at Genentech for nearly 23 years, most recently as Vice President and Global Head of Technical Development Project & Portfolio Management for the Roche large and small molecule development portfolio. Earlier he held several leadership roles spanning biologics manufacturing process development eventually becoming Vice President of Pharmaceutical Development.
Dana received a Ph.D. from Stanford following a B.S. from the University of Colorado at Boulder, both in chemical engineering with a focus on biological systems. He has held leadership positions in several scientific organizations, has chaired or co-chaired numerous sessions and scientific conferences, and is a fellow of the American Institute for Medical and Biological Engineering.